Drug candidate IRL1117 is developed as a once-daily oral treatment for the hallmark symptoms of Parkinson’s without inducing the troublesome complications caused by today’s mainstay anti-Parkinson’s levodopa treatments. Initiation of development towards clinical studies has commenced and IRL1117 is expected to be prepared to initiate Phase I studies in 2024.
IRL1117 will be developed as a once-daily oral treatment for the hallmark symptoms of Parkinson’s without inducing the troublesome complications caused by today’s mainstay levodopa-based treatments in Parkinson’s. IRL1117 is an orally available and potent dopamine D1 and D2 receptor agonist that has demonstrated rapid onset and more than 10 hours of sustained efficacy in preclinical studies.
At present, people with Parkinson’s disease are prescribed the anti-Parkinson’s treatment levodopa treating the hallmark symptoms of tremor, rigidity, and slowness of movement. Levodopa has been the mainstay treatment of Parkinson’s since the 1960s and is currently the only medication that provides adequate symptomatic relief of the disease during its progression. Levodopa has, however, significant treatment-related limitations, especially the short duration of action and the occurrence of troublesome treatment-related complications such as excessive involuntary movements. By comparison, IRL1117 offers a clearly differentiating alternative being orally available, potent and displaying a long-duration anti-parkinsonian efficacy without inducing the troublesome complications during long-term treatment in preclinical models of Parkinson’s.
IRL1117 continues with inhouse activities in preparation for Phase I enabling toxicology and manufacturing activities in 2024.
The P003 project aims to discover and develop dopamine D1 and D2 receptor agonist compounds with once-daily oral administration and improved efficacy on Parkinson’s core motor symptoms (tremor, rigidity, and slowness of movements) but are free from the limitations displayed by levodopa (i.e., the short duration of action and the motor complications). In addition to IRL1117, there are a number of follow-on compounds identified with differentiation relating to the onset of action and time to maximal efficacy.
About P003 project
The research project P003 aims to develop a novel treatment for Parkinson’s disease.
Committed to the discovery and development of treatments that transform the lives of people living with Parkinson’s.